| LncRNA | Compound | Condition | Effect | Throughput | PMID | Details |
|---|---|---|---|---|---|---|
| FENDRR | Doxorubicin (Adriamycin) | osteosarcoma | Sensitive | High | 26464619 | |
| FENDRR | Doxorubicin (Adriamycin) | osteosarcoma | Sensitive | Low | 26464619 | |
| MGC12916 | Doxorubicin (Adriamycin) | osteosarcoma | Resistant | High | 26464619 | |
| lnc-ADCY9-1 | Doxorubicin (Adriamycin) | osteosarcoma | Sensitive | Low | 26464619 | |
| lnc-CA5A-4 | Doxorubicin (Adriamycin) | osteosarcoma | Resistant | Low | 26464619 | |
| lnc-ZNF706-1 | Doxorubicin (Adriamycin) | osteosarcoma | Sensitive | Low | 26464619 | |
| FOXC2-AS1 | Doxorubicin (Adriamycin) | osteosarcoma | Resistant | Low | 26408180 | |
| FOXC2-AS1 | Doxorubicin (Adriamycin) | osteosarcoma | Resistant | High | 26464619 | |
| FOXC2-AS1 | Doxorubicin (Adriamycin) | osteosarcoma | Resistant | Low | 26464619 | |
| LINC00944 | Doxorubicin (Adriamycin) | osteosarcoma | Resistant | Low | 26464619 | |
| lnc-ANO9-1 | Doxorubicin (Adriamycin) | osteosarcoma | Resistant | High | 26464619 | |
| lnc-BCAN-1:1 | Doxorubicin (Adriamycin) | osteosarcoma | Resistant | Low | 26464619 | |
| SNHG10 | Doxorubicin (Adriamycin) | osteosarcoma | Resistant | High | 26464619 | |
| SNHG10 | Doxorubicin (Adriamycin) | osteosarcoma | Resistant | High | 26464619 | |
| SNHG10 | Doxorubicin (Adriamycin) | osteosarcoma | Resistant | Low | 26464619 | |
| lnc-RXRG-1 | Doxorubicin (Adriamycin) | osteosarcoma | Sensitive | High | 26464619 | |
| lnc-NBPF16-3 | Doxorubicin (Adriamycin) | osteosarcoma | Sensitive | High | 26464619 | |
| lnc-NBPF16-3 | Doxorubicin (Adriamycin) | osteosarcoma | Sensitive | Low | 26464619 | |
| PCGEM1 | Doxorubicin (Adriamycin) | prostate cancer | Resistant | Low | 16569192 | |
| C10orf101 | Doxorubicin (Adriamycin) | osteosarcoma | Sensitive | High | 26464619 | |
| lnc-RPS24-3 | Doxorubicin (Adriamycin) | osteosarcoma | Sensitive | Low | 26464619 | |
| MIR503HG | Doxorubicin (Adriamycin) | osteosarcoma | Sensitive | High | 26464619 | |
| MIR503HG | Doxorubicin (Adriamycin) | osteosarcoma | Sensitive | Low | 26464619 | |
| MT1CP | Doxorubicin (Adriamycin) | osteosarcoma | Sensitive | High | 26464619 | |
| LINC01116 | Doxorubicin (Adriamycin) | osteosarcoma | Sensitive | Low | 26464619 | |
| H19 | Doxorubicin (Adriamycin) | leukemia | Resistant | Low | 8674037 | |
| H19 | Doxorubicin (Adriamycin) | breast cancer | Resistant | Low | 8674037 | |
| H19 | Doxorubicin (Adriamycin) | hepatocellular carcinoma | Resistant | Low | 17297456 | |
| Lnc-VLDLR | Doxorubicin (Adriamycin) | hepatocellular cancer | Resistant | Low | 24874432 | |
| MRUL | Doxorubicin (Adriamycin) | gastric cancer | Resistant | Low | 24958102 | |
| lnc-PDGFRB | Doxorubicin (Adriamycin) | osteosarcoma | Sensitive | High | 26464619 | |
| lnc-PHLDA3 | Doxorubicin (Adriamycin) | osteosarcoma | Sensitive | High | 26464619 | |
| lnc-PRSS21 | Doxorubicin (Adriamycin) | osteosarcoma | Resistant | High | 26464619 | |
| lnc-COL6A1-1 | Doxorubicin (Adriamycin) | osteosarcoma | Resistant | High | 26464619 | |
| uc010lgv.1 | Doxorubicin (Adriamycin) | osteosarcoma | Resistant | High | 26464619 | |
| uc010lgv.1 | Doxorubicin (Adriamycin) | osteosarcoma | Resistant | Low | 26464619 | |
| uc003txt.3 | Doxorubicin (Adriamycin) | osteosarcoma | Resistant | High | 26464619 | |
| lnc-RP11-597K23.2.1-2 | Doxorubicin (Adriamycin) | osteosarcoma | Resistant | High | 26464619 | |
| LINC01116 | Doxorubicin (Adriamycin) | osteosarcoma | Sensitive | High | 26464619 | |
| uc002sts.4 | Doxorubicin (Adriamycin) | osteosarcoma | Sensitive | High | 26464619 | |
| uc003txt.3 | Doxorubicin (Adriamycin) | osteosarcoma | Resistant | Low | 26464619 | |
| uc002sts.4 | Doxorubicin (Adriamycin) | osteosarcoma | Sensitive | Low | 26464619 | |
| ARA | Doxorubicin (Adriamycin) | liver cancer | Resistant | Low | 24184505 | |
| ARA | Doxorubicin (Adriamycin) | breast cancer | Resistant | Low | 24184505 |